Moteur de recherche d’entreprises européennes
Financement de l’UE (6 940 517 €) : CAR-engineered Cell therapy for Cardiovascular diseases Hor 01/10/2026 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
CAR-engineered Cell therapy for Cardiovascular diseases
CARDIO will develop a next-generation immunotherapy based on gene-engineered regulatory T cells (Tregs) to restore immune homeostasis during acute and chronic inflammation in cardiovascular disease. Myocardial infarction (MI), often caused by atherosclerosis (AS), is a leading cause of death in Europe—affecting one in seven women and one in six men. MI results from thrombotic occlusion following plaque rupture or erosion, leading to myocardial ischemia, cell death, and a self-perpetuating inflammatory response. This unresolved inflammation impairs tissue repair, drives adverse remodeling, and contributes to both acute and chronic heart failure (HF), with devastating impacts on patient quality of life and survival. Given the heart’s negligible regenerative capacity, CARDIO will utilize Tregs to (i) suppress chronic inflammation within atherosclerotic plaques, preventing their rupture, and (ii) disrupt the acute inflammatory cycle post-MI to support myocardial healing. CARDIO Tregs will be derived from healthy donors as an allogeneic, virus-free gene-engineered “off-the-shelf” product. To enhance specificity and function, they will be equipped with chimeric antigen receptors (CARs) targeting myocardial (MYOCAR) and atherosclerotic (ASCAR) antigens. Upon antigen recognition, these CAR Tregs will secrete tolerogenic cytokines and suppress inflammatory macrophages and T cells—key drivers of fibrosis and plaque progression. Using in vivo CRISPR screening and protein engineering, CARDIO will tailor Tregs to inflammatory niches, ensuring stability and effective immune modulation. The ultimate goal is to deliver the first cellular immunotherapy for reducing atheroprogression and improving post-MI recovery—transforming outcomes for patients and reducing cardiovascular mortality.
| Bayerische Forschungsallianz Bavarian Research Alliance GmbH | 191 973 € |
| Cemm - Forschungszentrum Fuer Molekulare Medizin GmbH | 1 348 444 € |
| Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) | 526 661 € |
| DKMS Group gGmbH | 121 562 € |
| T-Curx GmbH | 1 046 000 € |
| Universitaet Fuer Bodenkultur Wien | 1 132 100 € |
| Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat | 2 573 777 € |
https://cordis.europa.eu/project/id/101289864
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.